The votes are in: six of seven recommended — and the committee overruled its own scientists on every one

We told you we'd report the votes, not the vibes. The hearing is done, and it's a genuinely significant result.

What's the "503A Bulks List"?

This is the thing everyone was actually voting on. Section 503A of federal law lets compounding pharmacies prepare custom medications for individual patients. The 503A Bulks List is the official roster of raw ingredients they're allowed to use for that.

Getting a peptide onto that list means a pharmacy may legally compound it with a prescription. It does not mean the FDA approved it as a drug, tested it, or found it effective — approval and compounding are entirely separate legal tracks. This distinction is the entire story this week, and almost every headline blurs it.

The final tally: six recommended, one rejected

Across the two-day July 23–24 hearing, the FDA's Pharmacy Compounding Advisory Committee voted to recommend six of the seven peptides for the 503A list — BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon — and rejected only Emideltide (DSIP). Every vote was close.

The headline underneath the headline: they overruled their own scientists on all of them. The FDA's career reviewers had submitted briefing documents opposing all seven, citing missing human data, poor chemical characterization, and specific safety flags — adverse-event reports for BPC-157, carcinogenicity questions around Epitalon's mechanism, anticoagulant signals for Semax. Reporters in the room described an audible gasp when the first BPC-157 tally was read, because a compounding panel voting against its own staff's written recommendation is close to unheard of. Then it happened six more times.

Why this happened is worth understanding honestly. The committee was hastily reassembled for this meeting, and reporting notes several members have ties to the peptide and telehealth industries. HHS Secretary RFK Jr., who oversees the FDA and has said he uses peptides himself, championed this outcome. When the first four passed, a major telehealth company's stock jumped more than 10% within hours — which tells you exactly who was waiting for this.

And now the part that gets lost — three separate things are being collapsed into one. There's (1) removal from the restricted list, (2) this PCAC recommendation, and (3) actual placement on the compoundable list after formal FDA rulemaking. This week cleared only the second — and only as advice the FDA can still reject.

Realistic timelines for a legal compounding pathway run twelve months or more, into 2027. Nothing is legal to compound today that wasn't yesterday. Anything sold to you right now as BPC-157, TB-500, or the rest remains an unregulated research chemical with no oversight of purity or dose.

The evidence didn't change. The vote did.

That's the single most important sentence about this week. No trial was published between the FDA's "no" and the committee's "yes." No new safety data appeared. The human evidence for these six peptides is exactly as thin today as it was when the FDA's own scientists reviewed it and recommended against every one.

If and when these become legally compoundable in 2027, they will be precisely as studied as they are right now — which, per the agency's review, means poor characterization and little-to-no human efficacy data for most of them.

The keeper concept: a favorable vote changed these peptides' legal trajectory without changing their scientific standing one inch. Those are different axes, and this week is the clearest demonstration you'll ever see of a compound moving on one while standing still on the other. When "FDA panel approved!" starts appearing in ads — and it will, fast — that's the sentence to remember.

Brace for the marketing, and change nothing about your framework

The marketing surge is already here. A telehealth industry that has spent two years turning compounded GLP-1s into a multibillion-dollar business is ready to do the same with wellness peptides — and a favorable advisory vote is exactly the credibility badge it wanted. You will see "FDA-backed" and "panel-approved" in peptide advertising aimed squarely at midlife women over the coming year. You now know precisely what those phrases do and don't mean.

None of the six changes your priorities. Look at the list — BPC-157, TB-500, MOTS-c and the rest are the recovery/longevity compounds, and their human evidence for midlife concerns remains thin. The peptides that actually earn a place for you are still the ones that weren't in this hearing: the FDA-approved GLP-1s (with the muscle-and-bone caveats), and topical GHK-Cu for skin. Collagen peptides remain a reasonable add-on. A committee vote doesn't move any of those.

And the sequence still holds. Foundation first — sleep, protein, strength. Then hormones, with a clinician who knows your history. Then, and only then, peptides with real evidence. Nothing about Silver Spring reordered that list.

The one to actually watch: GHK-Cu — the copper peptide genuinely relevant to midlife skin — comes before PCAC in the second meeting, expected before end of February 2027, alongside Melanotan II and three others. After what just happened, that meeting matters a great deal more than it did a week ago. We'll be there.

Educational, not medical advice. Always consult a qualified clinician before starting, stopping, or changing any treatment. Regulatory details current as of writing and subject to change.

← All issues